Home/Filings/4/0001628280-25-039730
4//SEC Filing

Tansey Casey M 4

Accession 0001628280-25-039730

CIK 0001464521other

Filed

Aug 10, 8:00 PM ET

Accepted

Aug 11, 9:00 PM ET

Size

54.9 KB

Accession

0001628280-25-039730

Insider Transaction Report

Form 4
Period: 2025-08-07
Transactions
  • Conversion

    Series C Preferred Stock

    2025-08-1121,2950 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (21,295 underlying)
  • Conversion

    Series D Preferred Stock

    2025-08-112,5860 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (2,586 underlying)
  • Conversion

    Convertible Promissory Note

    2025-08-1151,7360 total(indirect: By U.S. Venture Partners X, L.P.)
    Exercise: $15.20Common Stock (51,736 underlying)
  • Conversion

    Convertible Promissory Note

    2025-08-1116,4470 total
    Exercise: $15.20Common Stock (16,447 underlying)
  • Conversion

    Common Stock

    2025-08-11+98,30398,303 total(indirect: By USVP X Affiliates, L.P.)
  • Conversion

    Common Stock

    2025-08-11+16,44716,447 total
  • Conversion

    Series B-1 Preferred Stock

    2025-08-1110,5600 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (10,560 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2025-08-117,0400 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (7,040 underlying)
  • Conversion

    Series D Preferred Stock

    2025-08-1110,1060 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (10,106 underlying)
  • Conversion

    Common Stock

    2025-08-11+3,072,7593,072,759 total(indirect: By U.S. Venture Partners X, L.P.)
  • Conversion

    Series B-1 Preferred Stock

    2025-08-11220,0520 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (220,052 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2025-08-11330,0780 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (330,078 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2025-08-11220,0520 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (220,052 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2025-08-11330,0780 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (330,078 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2025-08-117,0400 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (7,040 underlying)
  • Conversion

    Series D Preferred Stock

    2025-08-113230 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (323 underlying)
  • Conversion

    Convertible Promissory Note

    2025-08-111,6550 total(indirect: By USVP X Affiliates, L.P.)
    Exercise: $15.20Common Stock (1,655 underlying)
  • Award

    Stock Option

    2025-08-07+47,42047,420 total
    Exercise: $19.00Exp: 2035-08-07Common Stock (47,420 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2025-08-1110,5600 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (10,560 underlying)
  • Conversion

    Series F Preferred Stock

    2025-08-111,164,1790 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (1,164,179 underlying)
  • Conversion

    Series F Preferred Stock

    2025-08-1137,2440 total(indirect: By USVP X Affiliates, L.P.)
    Common Stock (37,244 underlying)
  • Conversion

    Series C Preferred Stock

    2025-08-11665,6230 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (665,623 underlying)
  • Conversion

    Series D Preferred Stock

    2025-08-1180,8550 total(indirect: By U.S. Venture Partners X, L.P.)
    Common Stock (80,855 underlying)
Footnotes (7)
  • [F1]Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.
  • [F2]Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.
  • [F3]Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.
  • [F4]Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.
  • [F5]Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.
  • [F6]Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F7]The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

Issuer

Heartflow, Inc.

CIK 0001464521

Entity typeother

Related Parties

1
  • filerCIK 0001474322

Filing Metadata

Form type
4
Filed
Aug 10, 8:00 PM ET
Accepted
Aug 11, 9:00 PM ET
Size
54.9 KB